New medicines coming soon!
In preparation for the new year, we've provided a special advance listing of upcoming medicines that we are sure will be helpful to patients around the world.
1. Latanoprostene bunod ophthalmic solution (Vyzulta)
Vyzulta (latanoprostene bunod ophthalmic solution) is a prostaglandin analog approved by the FDA on November 2, 2017, for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. These are the first eyedrops to be approved in a while that reduce eye pressure. The product is intended to be easily applied once-daily.
2. Telotristat ethyl (Xermelo)Xermelo (telotristat ethyl) is a tryptophan hydroxylase inhibitor indicated for adults with severe diarrhoea associated with a condition called carcinoid syndrome. Carcinoid syndrome is a set of symptoms sometimes seen in people with carcinoid tumours, whose tumours release excess amounts of the hormone serotonin, resulting in diarrhea, flushing of the face and cramps.
3. Copanlisib (Aliqopa)Aliqopa (copanlisib) is a kinase inhibitor approved by the FDA on September 14, 2017, for the treatment of adults with relapsed follicular lymphoma who have received at least two prior treatments known as systemic therapies. Follicular lymphoma is the most common slow-growing form of Non-Hodgkin Lymphoma (NHL), accounting for approximately 12% of all B-cell NHLs.
4. Abemaciclib (Verzenio)Verzenio (abemaciclib) is a kinase inhibitor approved by the FDA on September 28, 2017 for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer:
If you want to know more about the release dates of these medicines - please contact our Support Team.